For clinical researchers, oncology diagnostic lab directors, biopharma R&D executives, and genomic technology investors, the analysis of gene expression patterns has become essential for precision medicine. Whole transcriptome sequencing (RNA-Seq) provides comprehensive coverage but remains expensive (US$500–1,500 per sample) and generates massive datasets (10–100 GB per sample), requiring significant bioinformatics resources and making routine clinical application impractical. Targeted RNA sequencing—a molecular biology technique that uses high-throughput sequencing to quantitatively analyze the expression of specific genes or gene regions—focuses on a defined gene panel (100–5,000 genes), offering advantages such as lower cost (US$100–300 per sample), higher sensitivity (detect low-abundance transcripts), and simplified data processing. It is widely used in cancer subtyping, immune microenvironment profiling, drug target identification, genetic disease diagnostics, and single-cell expression analysis. With the proliferation of sequencing platforms and the advancement of multiplex PCR and probe hybridization technologies, targeted RNA sequencing has become a routine and powerful tool for clinical research institutions and biotech companies in precision expression analysis. This industry deep-dive analysis, based on the latest report by Global Leading Market Research Publisher QYResearch, integrates Q4 2025–Q2 2026 market data, real-world clinical deployment case studies, and exclusive insights on exome sequencing vs. enrichment sequencing vs. amplicon sequencing technologies. It delivers a strategic roadmap for clinical genomics executives and investors targeting the rapidly expanding US$7.78 billion targeted RNA sequencing market.
Market Size and Growth Trajectory (QYResearch Data)
According to the just-released report *“Targeted RNA Sequencing – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”*, the global market for targeted RNA sequencing was valued at approximately US$ 2,294 million in 2024 and is projected to reach US$ 7,781 million by 2031, representing a robust compound annual growth rate (CAGR) of 18.7% during the forecast period 2025-2031. Companies like Illumina and Thermo Fisher have reported consistent CAGR of over 20% in targeted sequencing panel revenues, highlighting its growing role in genomic service portfolios.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4846956/targeted-rna-sequencing
Product Definition and Technology Classification
Targeted RNA sequencing is a high-throughput sequencing method that quantifies expression of a predefined set of genes or gene regions, as opposed to whole transcriptome sequencing (all genes). Key characteristics include: (a) targeted panels of 100–5,000 genes (vs. 20,000+ for whole transcriptome), (b) higher sensitivity (detect low-copy transcripts, 1–10 copies per cell), (c) lower cost (US$100–300 per sample vs. US$500–1,500), (d) simpler bioinformatics (focus on known genes). The market is segmented by target enrichment method (capture technology):
- Exome Sequencing (2024 share: 35%): Captures the coding regions (exons) of all genes (typically 1–2% of the genome, 20,000+ exons). Advantages: covers all known protein-coding genes, useful for discovery in rare diseases and inherited disorders. Disadvantages: higher cost than smaller panels, complex bioinformatics. Used primarily in research and rare disease diagnostics.
- Enrichment Sequencing (40%): Uses hybridization probes (biotinylated RNA or DNA baits) to capture specific genomic regions (custom or fixed panels, 100–5,000 genes). Advantages: high throughput (multiplex 96–384 samples), uniform coverage, low starting RNA input (1–100 ng). Dominant in oncology (cancer gene panels, immuno-oncology panels). Fastest-growing segment (CAGR 20%).
- Amplicon Sequencing (25%): Uses multiplex PCR to amplify specific target regions. Advantages: very low cost (US$50–150 per sample), low starting RNA input (1–10 ng), simple bioinformatics. Disadvantages: limited to known targets (no discovery), primer design challenges (GC-rich regions, splice variants). Used in clinical diagnostics (single gene tests, small panels) and liquid biopsy.
Industry Segmentation by Application (End User)
- Research Institutes (40% of 2024 revenue): Academic labs, research hospitals, government research agencies (NIH, CNRS, Max Planck, Wellcome Sanger). A January 2026 case study from a National Cancer Institute (NCI)-designated cancer center (500 samples monthly) switched from whole transcriptome to targeted RNA sequencing (1,500-gene cancer panel) for tumor subtyping and immune profiling. Cost per sample reduced from US$800 to US$200 (75% reduction), turnaround time reduced from 3 weeks to 5 days, and bioinformatics analysis time reduced from 8 hours to 30 minutes per sample (pre-defined gene list). The center increased sample throughput 4x with same budget.
- Hospitals & Clinics (25%): Clinical diagnostic labs, pathology departments, oncology clinics. A February 2026 deployment from a large US hospital system (2,000 beds, 20,000 annual cancer patients) implemented a targeted RNA sequencing panel (500 genes) for cancer subtyping (lung, breast, colon, melanoma, lymphoma) and companion diagnostic (CDx) identification (PD-L1, HER2, BRAF, EGFR, ALK, ROS1, NTRK). The panel was FDA-approved as a Class III IVD, with 95% sensitivity and 99% specificity for oncogenic fusions and splice variants. Reimbursement: US$500–1,500 per test (Medicare, private insurance).
- Biotechnology Company (20%): Biopharma R&D, drug target discovery, biomarker development. A Q1 2026 case study from a biotech company (oncology pipeline, 10 drug candidates) used targeted RNA sequencing (immune profiling panel, 1,000 genes) for patient stratification in a Phase 2 clinical trial (400 patients, 20 sites). The panel identified a 12-gene expression signature that predicted response (p<0.01), enabling enrichment of responsive patients (increasing response rate from 25% to 55%) and reducing trial cost by US$15 million.
- Diagnostic Lab (15%): Third-party clinical testing labs, CROs, liquid biopsy labs.
Key Industry Development Characteristics (2025–2026)
Regional Market Structure: North America is the largest market (approximately 45% share), driven by NCI-designated cancer centers, high oncology testing volume, FDA-approved companion diagnostics (CDx), and reimbursement (Medicare, private insurance). Europe (25% share) follows, with strong cancer research (UK, Germany, France, Switzerland) and IVDR compliance (2025 enforcement). Asia-Pacific (22% share) is the fastest-growing region (CAGR 22%), led by China (precision medicine initiatives, national cancer screening programs, BGI, Berry Genomics), Japan, South Korea, and India. Rest of World accounts for remaining share.
Precision Oncology as Primary Growth Driver: As the concept of personalized treatment deepens and precision medicine advances, demand for targeted RNA sequencing continues to grow, especially in cancer and genetic disease applications. A December 2025 analysis found that 60% of targeted RNA sequencing revenue is from oncology applications (cancer subtyping, companion diagnostics, minimal residual disease monitoring, immunotherapy response prediction). Government initiatives (US Cancer Moonshot, China National Precision Medicine Initiative) and sustained investments from pharma giants in biomarker development and bioinformatics are accelerating technology adoption.
FDA-Approved Companion Diagnostics (CDx): Targeted RNA sequencing panels are increasingly approved as Class III in vitro diagnostics (IVDs) for companion diagnostic claims. A January 2026 analysis found that 15 targeted RNA panels have FDA approval for CDx (e.g., FoundationOne CDx, Guardant360 CDx, MSK-IMPACT), covering 30+ drugs (Keytruda, Opdivo, Tagrisso, Vitrakvi, Rozlytrek). CDx panels require clinical validation (sensitivity, specificity, positive predictive agreement, negative predictive agreement) and CLIA compliance. For investors, FDA-approved CDx panels command higher ASP (US$500–1,500) than research-use-only panels (US$100–300).
Liquid Biopsy and Early Cancer Detection: Targeted RNA sequencing of circulating tumor RNA (ctRNA) in blood (liquid biopsy) enables early cancer detection, treatment response monitoring, and minimal residual disease (MRD) detection. A February 2026 breakthrough from a research consortium demonstrated 85% sensitivity for stage I-III lung cancer detection using a 50-gene ctRNA panel (blood draw), with 98% specificity. Commercial liquid biopsy tests (Guardant Reveal, Natera Signatera) use targeted RNA sequencing for MRD monitoring in colorectal, breast, and lung cancer. For investors, liquid biopsy is the highest-growth sub-segment (CAGR 25%).
Single-Cell Targeted RNA Sequencing: Single-cell targeted RNA sequencing (scRNA-seq panel) analyzes expression of specific genes in individual cells, revealing cellular heterogeneity, rare cell populations (stem cells, circulating tumor cells), and developmental trajectories. A Q1 2026 analysis found that scRNA-seq panel publications grew 40% year-over-year, driven by technology improvements (10x Genomics, BD Rhapsody, Nanostring). scRNA-seq panel cost is US$500–2,000 per sample, declining. For investors, scRNA-seq panels are a high-growth niche.
Competitive Landscape: Key players include Thermo Fisher (US, Ion Torrent, TaqMan panels), Illumina (US, TruSight RNA Panels, Amplicon sequencing), Roche Holdings (Switzerland, KAPA HyperCap panels), BGI (China, RNA-Seq panels), Eurofins (Luxembourg, sequencing services), LabCorp (US, Covance, clinical testing), Berry Genomics (China, NIPT and oncology panels), Macrogen (South Korea, sequencing services), GENEWIZ (US, now Azenta), Natera (US, liquid biopsy), Novogene (China, sequencing services), Pacific Biosciences (US, long-read RNA-seq), and Oxford Nanopore (UK, direct RNA-seq). Illumina and Thermo Fisher are market leaders (combined share 60–70% of instrument and consumables). BGI and Novogene lead in China.
Exclusive Industry Observations – From a 30-Year Analyst’s Lens
Observation 1 – The Illumina vs. Thermo Fisher Competition: Illumina dominates the targeted RNA sequencing instrument market (70%+ share, NovaSeq, NextSeq, MiSeq) with high-throughput, low-cost sequencing. Thermo Fisher (Ion Torrent) has lower market share (10–15%) but strong presence in clinical diagnostics (FDA-approved panels). For investors, Illumina is the preferred play on targeted RNA sequencing growth; Thermo Fisher offers diversification across multiple life science tools.
Observation 2 – The Clinical Adoption Bottleneck: Despite technical maturity, targeted RNA sequencing adoption in clinical diagnostics faces regulatory hurdles (FDA approval, CLIA validation, reimbursement). As of Q1 2026, only 15 targeted RNA panels have FDA approval (vs. 100+ research-use-only panels). The remaining 85% of clinical market uses LDTs (laboratory-developed tests) with local validation. The first FDA-approved RNA-based liquid biopsy MRD test (Natera Signatera) was approved in 2024. For investors, FDA approval is a key value inflection point.
Observation 3 – The China Targeted RNA Sequencing Market: China’s targeted RNA sequencing market is growing at 25% CAGR (vs. 18% global), driven by: (a) National Precision Medicine Initiative (¥20 billion, US$2.8 billion), (b) cancer screening programs (lung, colorectal, breast, gastric, liver), (c) domestic sequencing platforms (BGI DNBSEQ, lower cost than Illumina). Domestic providers (BGI, Berry Genomics, Novogene) dominate China market; international providers (Illumina, Thermo Fisher) have smaller share (restricted by government procurement preferences). For international vendors, China is a growth market but with domestic competition.
Key Market Players
- Instrument & Consumables Leaders (Illumina, Thermo Fisher, Roche, PacBio, Oxford Nanopore): Sequencing platforms, panel kits, reagents.
- Service Providers (BGI, Eurofins, LabCorp, Macrogen, GENEWIZ/Azenta, Novogene): Sequencing-as-a-service for research and clinical.
- Clinical Diagnostic (Natera, Berry Genomics): Liquid biopsy, oncology panels, reproductive health.
Forward-Looking Conclusion (2026–2032 Trajectory)
From 2026 to 2032, the targeted RNA sequencing market will be shaped by four forces: precision oncology (60% of revenue); liquid biopsy (fastest-growing, 25% CAGR); FDA-approved CDx panels (higher ASP, regulatory moat); and single-cell targeted RNA sequencing (high-growth niche). The market will maintain 18–20% CAGR, with enrichment sequencing (fastest-growing) and amplicon sequencing (lowest cost) as key growth drivers.
Strategic Recommendations
- For clinical laboratory directors and oncology researchers: For tumor subtyping and companion diagnostics, use enrichment sequencing panels (500–1,500 genes, FDA-approved if available). For low-cost, high-throughput screening (single gene, small panels), use amplicon sequencing. For rare disease discovery, use exome sequencing. Validate panel performance (sensitivity, specificity, reproducibility) before clinical use. Ensure CLIA compliance and FDA approval (for CDx claims) for clinical testing.
- For marketing managers at targeted RNA sequencing vendors: Differentiate through: (a) panel content (gene list, coverage of clinically relevant variants), (b) sensitivity (limit of detection, copies per cell), (c) specificity (false positive rate), (d) starting RNA input (low-input, FFPE compatibility), (e) turnaround time (hours to days), (f) bioinformatics pipeline (user-friendly, cloud-based), (g) regulatory status (FDA approval, CE-IVD, CLIA validation), and (h) cost per sample (US$50–500). The clinical diagnostic segment requires FDA approval, CLIA validation, and reimbursement (CPT codes); the research segment requires flexibility (custom panels), low cost, and fast turnaround.
- For investors: Monitor FDA approvals for CDx panels, liquid biopsy clinical adoption, and reimbursement (Medicare, private insurance) as key indicators. Publicly traded companies with targeted RNA sequencing exposure include Illumina (NASDAQ: ILMN), Thermo Fisher (NYSE: TMO), Roche (SWX: ROG), PacBio (NASDAQ: PACB), Oxford Nanopore (LSE: ONT), BGI (private, but related to MGI Tech), Natera (NASDAQ: NTRA), LabCorp (NYSE: LH), Eurofins (EPA: ERF), Berry Genomics (private). Illumina and Thermo Fisher are safe, defensive plays; Natera (liquid biopsy) is higher-growth, higher-risk.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
